Trial Profile
Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Temozolomide
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- 01 Jul 2021 Results (n=508) assessing Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma published in the Neuro-Oncology
- 14 Nov 2017 Status changed from active, no longer recruiting to completed.
- 07 Jun 2016 Results (n=367) assessing a genome-wide analysis of genetic variation associated wit hthe vasular toxicities presented at the 52nd Annual Meeting of the American Society of Clinical Oncology